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IKKa Is a p63 Transcriptional Target Involved in the
Pathogenesis of Ectodermal Dysplasias
Barbara Marinari1,7, Costanza Ballaro2,7, Maranke I Koster3, Maria Laura Giustizieri1, Francesca Moretti1,
Francesca Crosti4, Marina Papoutsaki1, Michael Karin5, Stefano Alema2, Sergio Chimenti1, Dennis R Roop3
and Antonio Costanzo1,6
The transcription factor p63 plays a pivotal role in the development and differentiation of the epidermis and
epithelial appendages. Indeed, mutations in p63 are associated with a group of ectodermal dysplasias
characterized by skin, limb, and craniofacial defects. It was hypothesized that p63 exerts its functions by
activating specific genes during epidermal development, which in turn regulate epidermal stratification and
differentiation. We have identified I-kappaB kinase alpha (IKKa) as a direct transcriptional target of p63 that is
induced at early phases of terminal differentiation of primary keratinocytes. We show that the DNp63 isoform is
required for IKKa expression in differentiating keratinocytes and that mutant p63 proteins expressed in
ectodermal dysplasia patients exhibit defects in inducing IKKa. Furthermore, we observed reduced IKKa
expression in the epidermis of an ankyloblepharon ectodermal dysplasia clefting patient. Our data demonstrate
that a failure to properly express IKKa may play a role in the development of ectodermal dysplasias.
Journal of Investigative Dermatology (2009) 129, 60–69; doi:10.1038/jid.2008.202; published online 17 July 2008
INTRODUCTION
The transcriptional activator p63 is a p53 paralog that is
expressed in basal cells and somatic stem cells of stratified
epithelia, in myoepithelial cells of the breast, salivary glands,
and in the proliferative compartment of gastric mucosa (Yang
et al., 1998, 1999). Owing to the use of two promoters and
complex alternative splicing, p63 encodes six isoforms (Yang
et al., 1998). Of these, TA isoforms structurally resemble p53
and contain an N-terminal transactivation domain, whereas
Delta-N (DN) isoforms lack this transactivation domain (Yang
et al., 1998). Dominantly inherited mutations in the p63 gene
are found in a number of human ectodermal dysplasias,
including ectrodactyly ectodermal dysplasia-cleft lip/palate
(EEC) syndrome, limb-mammary syndrome (LMS), ankylo-
blepharon ectodermal dysplasia clefting (AEC) and non-
syndromic split-hand/split-foot malformation (SHFM) (Rinne
et al., 2006). Genotype–phenotype correlations exist in that
mutations causing EEC syndrome, for example, are not found
in AEC, LMS, or SHFM (van Bokhoven and Brunner, 2002).
Moreover, there is a clear correlation between the position
where the mutation occurs and the observed syndrome. The
majority of mutations found in the EEC syndrome are
missense mutations generating amino acid substitutions in
residues predicted to contact DNA (Rinne et al., 2006). As the
DNA binding domain is present in all p63 isoforms, all
isoforms of p63 are affected by these mutations. Mutations in
exon 13 and exon 14, affecting only the a-isoforms of p63,
are almost exclusively associated with AEC (McGrath et al.,
2001; Rinne et al., 2006). DNA-binding mutants often act as
dominant-negative molecules, although whether this is also
the case for mutant p63 proteins remains to be determined.
Mice lacking p63 die soon after birth with several
developmental defects, particularly in limb and skin deve-
lopment (Mills et al., 1999; Yang et al., 1999). Defects in limb
morphogenesis in p63 null mice were evident as early as
embryonic day 9.5 (E9.5). In wild-type (wt) mice, during this
interval, p63 is expressed in the surface ectoderm as well as in
the ectoderm covering the limb buds and branchial arches.
Although still a matter of debate (Laurikkala et al., 2006; Suh
et al., 2006), it has been found that TAp63 isoforms, the first
p63 isoforms expressed during epidermal development, are
required for the commitment to stratification while they inhibit
terminal differentiation (Koster and Roop, 2004; Koster et al.,
2004). After commitment to stratification has occurred, DNp63
isoforms induce the expression of genes that are required for
later stages of epidermal morphogenesis (Koster et al., 2007).
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Interestingly, I-kappaB kinase alpha (IKKa)-deficient mice
display developmental defects, including skin, craniofacial,
and limb defects, showing some similarities with p63 null
mice (Hu et al., 1999; Li et al., 1999; Mills et al., 1999;
Takeda et al., 1999; Yang et al., 1999). Although IKKa is a
protein kinase that is part of the IKK complex, its role in
epidermal differentiation is independent of its kinase activity
or NF-kB activation (Hu et al., 1999). Interestingly, expres-
sion of IKKa in the epidermis is required not only for
epidermal development but also for the development of
tissues derived from the mesoderm and neural crest (limbs
and craniofacial structures) (Sil et al., 2004) and to switch on
the differentiative program by favoring keratinocyte cell cycle
arrest (Descargues et al., 2008). A recent study (Candi et al.,
2006) has identified IKKa as a transcriptional target for p63
with TAp63 being a better activator than DNp63 in
transcriptional assays. In our previous work (Koster et al.,
2007), we showed that epidermal-specific DNp63 down-
regulation in mice leads to increased keratinocyte prolifera-
tion, which correlates with reduced expression of IKKa.
Furthermore, these mice display a skin phenotype character-
ized by skin fragility that may resemble that of AEC patients
(Koster et al., 2007). We thus hypothesized that IKKa and p63
may genetically also interact in human cells, with IKKa
functioning downstream of p63. Furthermore, we hypothe-
sized that mutant p63 proteins expressed in ectodermal
dysplasia patients may interfere with the induction of IKKa
expression and that the alteration of this pathway may
contribute to the phenotype observed in ectodermal dysplasia
patients. In this study, we show that p63 directly induces
IKKa transcription and that mutant p63 proteins expressed in
ectodermal dysplasia patients interfere with IKKa induction.
RESULTS
IKKa is a direct transcriptional target of p63 in keratinocytes
IKKa promoter contains at least three potential p63 respon-
sive elements (Osada et al., 2005a, b; Candi et al., 2006). To
determine whether p63 could induce IKKa transcription, we
generated a luciferase reporter construct (IKKa-luc) contain-
ing a 1.2 kb fragment of the IKKa promoter and performed
transient transactivation assays. Exogenously expressed
DNp63a, DNp63b, DNp63g, and TAp63g strongly induced
the IKKa reporter construct, whereas TAp63a and TAp63b
weakly induced this reporter (Figure 1a). We also observed
activation of the IKKa promoter by exogenously expressed
DNp73a and TAp73a (Figure 1a). In contrast, p53 expression
did not induce transcription from the IKKa promoter either in
U2OS cells (Figure 1a) or in the immortalized keratinocyte
cell line HaCaT (data not shown). Although this is in
disagreement with the previously described role of p53 as a
transcriptional repressor of IKKa in an acute lymphoblastic
leukemia cell line (Gu et al., 2004), this discrepancy could
potentially be explained by cell-type specificity.
The ability of p63 to induce endogenous IKKa expression
was tested in transient expression experiments in U2OS
cells. As shown in Figure 1b, exogenously expressed DNp63
and DNp73 isoforms induced an increase in the levels of
endogenous IKKa mRNA (left panel) and protein (right panel)
better than the TA isoforms did. Expression levels of different
p63 and p73 isoforms are shown in Figure S1A.
To determine if p63 isoforms directly interact with the
IKKa promoter, we carried out chromatin immunoprecipita-
tion (ChIP) experiments after transient transfection of U2OS
cells with myc-tagged p63 expression plasmids. Cross-linked
chromatin was immunoprecipitated with specific antibodies
(Abs), and the presence of recovered IKKa promoter
fragments was analyzed by PCR using primers specific for
the proximal region of the putative IKKa promoter. Quanti-
fication of p63-bound IKKa promoter fragments after normal-
ization to the amount of transfected p63 protein (Figure S1B)
indicated that DNp63a, TAp63g, and DNp63g had a higher
affinity for the IKKa promoter than TAp63a did (Figure 1c, left
panel). The ChIP assay was repeated in primary human
keratinocytes placed under proliferating or differentiating
conditions (Figure 1c, right panel). We observed a transient
increase in p63 binding to IKKa promoter peaking 8 hours
after differentiation stimulus (Figure 1c, right panel).
These data indicate that p63 isoforms can induce IKKa
transcription, acting most likely through direct binding to its
promoter.
DNp63 induces IKKa during keratinocyte differentiation
To study the regulation of IKKa transcription during
keratinocyte differentiation, we examined IKKa mRNA levels
by real-time quantitative PCR (RT-qPCR) in normal human
epidermal keratinocytes (NHEK) subjected to a differentiation
stimulus (2mM CaCl2). IKKa mRNA levels increased at early
times (8 and 24 hours) after the induction of NHEK
differentiation (Figure 2a, left panel). As expected, DNp63
mRNA levels decreased upon differentiation (Figure 2a, right
panel), suggesting that p63 may be required to induce IKKa
transcription but not to maintain it. The early induction of
IKKa transcription upon keratinocyte differentiation corre-
lates with high levels of IKKa protein expression in the nuclei
of basal and suprabasal keratinocytes in normal human skin
(Figure 2b, upper panels) and colocalization of IKKa with p63
in most cells of the basal and suprabasal layers (Figure 2b,
lower panels). To determine whether the subcellular locali-
zation of IKKa was also affected by differentiation of human
keratinocytes, we performed immunoblotting using an anti-
IKKa Ab on cytoplasmic and nuclear extracts of normal
human keratinocytes. We observed an increase in the nuclear
fraction of IKKa protein upon keratinocyte differentiation
(Figure 2c), confirming previous observations obtained in
mouse keratinocytes (Sil et al., 2004; Descargues et al.,
2008).
To determine whether DNp63 proteins are involved in
IKKa induction, we used small interfering RNAs (siRNAs) to
selectively downregulate DNp63 transcripts in primary
keratinocytes. The specificity of siRNAs was determined by
transient transfection experiments performed in U2OS cells
in which we co-transfected expression plasmids encoding for
DNp63 together with control siRNAs (GFPsiRNA), DNp63-
specific, or TAp63-specific siRNAs. We observed a high
efficiency of DNp63-specific siRNA in downregulating
DNp63 protein expression (Figure 3a, left panel). The same
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siRNAs were used to downregulate endogenous DNp63 in
primary human keratinocytes (Figure 3a and b) or in primary
mouse keratinocytes (Figure S2). The transfection of DNp63
siRNAs resulted in a marked downregulation of DNp63
expression in both proliferating and differentiating keratino-
cytes. Downregulation of DNp63 had no effect on the
basal levels of IKKa protein, whereas calcium-induced levels
of IKKa were significantly decreased in DNp63-silenced
cells (Figure 3a, right panel). DNp63 downregulation also
decreased the expression of K1 early differentiation marker
(Figure 3a, right panel). These results were confirmed by
evaluating the levels of IKKamRNA in keratinocytes in which
DNp63 was downregulated (Figure 3b), and suggest that
DNp63 is involved in the induction of IKKa at early phases of
keratinocyte differentiation. Indeed, the downregulation of
DNp63 also resulted in a failure to induce early differentia-
tion markers of keratinocytes such as K1 (Figure 3b, right
panel), indicating that DNp63 controls the formation of
suprabasal layers. We also confirmed these results in primary
mouse keratinocytes (Figure S2). In addition, as DNp63
expression levels are reduced in the suprabasal layers of the
epidermis (Yang et al., 1998), these data are consistent with
the existence of DNp63-independent mechanisms for main-
taining IKKa expression in terminally differentiated cells.
In addition to reduced levels of K1 differentiation markers,
DNp63-downregulated cells also display increased prolifera-
tion as determined by BrdU incorporation assay (Figure 3c).
This is consistent with the observation made on the DNp63-
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Figure 1. p63 activates IKKa transcription. (a) p63 activates IKKa reporter gene. U2OS cells were transfected with IKKa reporter plasmid (0.1 mg), pRL-null
plasmid (0.02 mg), and expression vectors for different p63 and p73 isoforms or p53 (1.5 mg). After 24 hours, cells were harvested and luciferase activity was
determined (left panel). Protein expression was evaluated by western blot analysis with anti-Myc, anti-HA, and anti-p53 antibody (Ab) (right panel). (b)
Exogenously expressed p63 and p73 isoforms induce IKKa mRNA and protein expressions. U2OS cells were transfected with 2 mg of the indicated plasmid in
35mm dishes. Cells were harvested 24 hours after transfection and total mRNA was extracted and used for RT-qPCR. Results are expressed as IKKa expression
relative to ARP (human acidic ribosomal protein P0) expression (left panel). In a parallel experiment, U2OS cells were transfected with 2 mg of the indicated
plasmid in 35mm dishes. Cells were harvested 24 hours after transfection, and total cell lysates (25 mg) were subjected to immunoblot analysis with an anti-IKKa
Ab to determine IKKa expression. Actin expression was determined as a loading control. Levels of expression relative to pCDNA (Ctr)-transfected cells are
indicated (right panel). (c) p63 and p73 directly interact with the IKKa promoter. U2OS cells were transfected with the indicated plasmids. Cells were subjected
to ChIP, and the recovered chromatin was amplified with IKKa promoter-specific primers and normalized to protein expression (Figure S1). The ChIP assay was
repeated on primary human keratinocytes under proliferating or differentiating conditions using anti-p63-specific polyclonal Abs (right panel).
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knockdown mice skin (Koster et al., 2007) and with the
phenotype of AEC skin (Figure 5c). Given the role of IKKa as a
critical regulator of cell cycle exit in keratinocytes (Koster
et al., 2007; Descargues et al., 2008), we attempted to rescue
the correct proliferation rate by reintroducing IKKa in
DNp63-deficient keratinocytes. To this aim, human keratino-
cytes were transfected with control or DNp63-specific
siRNAs and then infected with mock or IKKa-expressing
adenoviruses and placed under differentiation conditions.
Twenty-four hours after infection, BrdU assay was performed
to determine the proliferation rate. As shown in Figure 3c, the
reintroduction of IKKa in keratinocytes restored low pro-
liferation rate. These data suggest that IKKa may act as the
DNp63 target gene required for correct exit from the cell
cycle upon differentiation stimulus, a step necessary to
achieve terminal differentiation.
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Figure 2. Nuclear IKKa expression increases at the onset of keratinocyte terminal differentiation. (a) IKKa expression increases at the onset of keratinocyte
differentiation. Human primary keratinocytes were treated with 2mM CaCl2 for 8 or 24 hours. Relative mRNA abundance was determined by RT-qPCR for IKKa,
K1 (left panel), or DNp63 (right panel). (b) p63 and IKKa colocalize in keratinocytes in human epidermis. Immunohistochemical staining of normal skin sections
was performed with a monoclonal anti-IKKa antibody (Ab) (see the Materials and Methods section), and upper panels represent original magnifications of  10
and  40 acquisition of the same section. Analysis of IKKa and p63 expressions in the human epidermis was performed by confocal microscopy after
immunofluorescence staining (scale bar¼20 mm). (c) IKKa nuclear translocation is induced by CaCl2 treatment. Human primary keratinocytes were treated with
2mM CaCl2. Cells were harvested 24 hours after treatment, and nuclear/cytoplasmic extracts were analyzed by western blot analysis using an anti-IKKa Ab.
Actin, b-tubulin, and g-tubulin expressions were used as a loading control to determine the purity of cytoplasmic extracts.
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p63 mutant proteins expressed in ectodermal dysplasia patients
influence IKKa transcription
Given that some defects observed in ectodermal dysplasias
caused by p63 mutations are also present in IKKa knockout
mice, we hypothesized that mutant p63 proteins expressed in
ectodermal dysplasia patients may have a reduced ability to
induce IKKa. To test this hypothesis, we determined the
ability of mutant DNp63 proteins to activate the IKKa reporter
gene and to induce endogenous IKKa expression. To this aim,
we used expression plasmids expressing different p63
mutants found in ectodermal dysplasias including DNA
binding domain mutants (DNp63a-306) and truncation
mutants (DNp63a-fs) of EEC syndrome, DNp63a-518 and
DNp63a-536 SAM domain mutants of AEC syndrome,
DNp63a-DAA of LMS, and DNp63a-639 of SHFM (Figure
4a). We initially performed transcriptional assays in the
epithelial cell line TE1 (North et al., 2002) and observed that
mutant DNp63a proteins expressed in EEC and AEC patients
(DNp63a-EEC and DNp63a-AEC, respectively) displayed a
reduced ability to activate the IKKa reporter gene (Figure 4b).
In particular, DNp63a-AEC proteins had a reduced ability to
activate the IKKa reporter construct. Similarly, mutant
DNp63a-EEC proteins showed a reduced ability to activate
the IKKa reporter construct. Mutant DNp63a proteins
expressed in LMS and SHFM patients (DNp63a-LMS and
DNp63a-SHFM, respectively), on the contrary, did not show
significant differences in their ability to activate the IKKa
reporter (Figure 4b).
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Figure 3. DNp63 is required for induction of IKKa expression by differentiation. (a) Specificity of DNp63 siRNAs. U2OS cells were co-transfected with 1mg of
Myc-tagged DNp63a expression plasmids, and the indicated siRNAs and cell lysates were subjected to immunoblotting with anti-myc or anti-actin antibodies
(left panel); primary human keratinocytes were transfected with specific siRNAs and then kept under proliferating or differentiating (2mM CaCl2) conditions.
After 24 hours, cells were harvested and 25 mg of total lysates were subjected to immunoblot analysis to verify p63, IKKa, K1, or actin expression levels (right
panel). Expression levels relative to control (first lane) were quantified. (b) The downregulation of DNp63 isoforms abrogates CaCl2-induced activation of IKKa
transcription. Primary human keratinocytes maintained under proliferating or differentiating (2mM CaCl2) conditions were transiently transfected with specific
siRNAs. Relative mRNA abundance was determined by RT-qPCR for IKKa (left panel) and K1 (right panel). (c) Reintroduction of IKKa in DNp63-deficient
keratinocytes restores calcium-induced exit from the cell cycle. Primary keratinocytes were transfected with indicated siRNAs. Sixteen hours after transfection,
cells were infected with Ad-IKKa. The next day, the cells were induced to differentiate by the addition of calcium (2mM). BrdU was then added for 6 hours and
its incorporation measured by a specific kit. Results are expressed as percentage of positive cells and error bars represent SD. Results are representative of three
independent experiments.
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The analysis of IKKa mRNA transcript levels in TE1 cells
transfected with DNp63a-AEC or DNp63a-EEC constructs
confirmed the defective ability of DNp63a-AEC and DNp63a-
EEC to induce IKKa transcription and showed reduced ability
of the LMS mutant to induce accumulation of IKKa mRNA
(Figure 4c). Similar results were obtained in the U2OS cell
line (data not shown).
p63 mutations that cause ectodermal dysplasias are
heterozygous, and mutant p63 proteins expressed in ecto-
dermal dysplasia patients may have a dominant-negative
effect toward wt p63 on the activation of p63 target genes. To
test this hypothesis, we determined the ability of mutant p63
proteins to interfere with IKKa induced by exogenously
expressed wt DNp63a in TE1 cells. As shown in Figure 5a,
DNp63a-AEC, DNp63a-EEC, and DNp63a-LMS proteins
impaired the ability of wt DNp63a to induce IKKa mRNA,
indicating their capacity to act in a dominant-negative
manner. To further confirm this observation, we analyzed
the expression levels of IKKa protein in TE1 cells transfected
with DNp63a in the presence of mutant DNp63a proteins
(Figure 5b). Densitometric quantification of IKKa expression
levels confirmed that DNp63-FS (EEC) and DNp63-536 (AEC)
exert a dominant-negative activity, that DNp63-306 (EEC) has
low interference potency, that and DNp63-639 (SHFM) does
not interfere at all with DNp63a-induced IKKa expression.
The dominant-negative activity of p63 mutants is also
demonstrated by their ability to block differentiation-induced
activation of IKKa reporter transcription (Figure S3).
To confirm that DNp63a-AEC proteins function as
dominant-negative molecules, we analyzed the epidermis
of an AEC patient carrying the I537T mutation. We
determined the expression of IKKa, K1, and Ki-67 by
immunohistochemistry on the lesional skin. As shown in
Figure 5c, IKKa expression is drastically reduced in AEC skin
as compared with normal skin of a control subject (Figure 5c,
left panels). Furthermore, we observed delayed K1 expres-
sion, which is present only in the upper layers of AEC skin,
and an increase in the expression of the proliferation marker
Ki-67 (Figure 5c, middle and right panels). IKKa down-
regulation in AEC skin is most likely due to reduced
transcription, as determined by the analysis of IKKa mRNA
levels extracted from AEC skin tissue (Figure 5c right
histogram).
Taken together, our data demonstrate that DNp63a
directly induces expression of IKKa and that reduced IKKa
expression, caused by expression of mutant p63 proteins,
may contribute to the development of the clinical phenotype
observed in ectodermal dysplasias.
DISCUSSION
Epidermal morphogenesis is a tightly regulated process that
involves the temporally coordinated activation of specific sets
of genes required for keratinocytes to achieve the subsequent
differentiation step (Koster and Roop, 2004). In addition,
many genes required for the execution of the epidermal
stratification program also mediate epithelial–mesenchymal
interactions, thus contributing to the formation of epithelial
appendages. Analysis of the phenotypes of p63 and IKKa
knockout mice indicated that p63 and IKKa belong to this
category of genes (Li et al., 1999; Mills et al., 1999; Takeda
et al., 1999; Yang et al., 1999; Koster and Roop, 2004; Sil
et al., 2004).
Our results demonstrate that p63 and IKKa are part of the
same genetic pathway, with p63 directly inducing transcrip-
tion of IKKa. The transcriptional activation of IKKa occurs
early upon differentiation of cultured keratinocytes. The
subsequent translocation of IKKa to the nucleus is required
for the role of IKKa in keratinocyte differentiation. All
three DNp63 isoforms and, to a lesser extent, TAp63g
can transcriptionally activate IKKa when overexpressed.
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Figure 4. Transcriptional regulation of the IKKa promoter by DNp63a
mutants expressed in ectodermal dysplasias. Transcriptional regulation of the
IKKa promoter by DNp63a mutants expressed in ectodermal dysplasias. (a)
Expression levels of myc-tagged wt DNp63a and DNp63a mutants L518V,
Q536L, FS, C306R, 1743 DelAA, and E639X were analyzed in TE1 cells by
immunoblot with an anti-myc antibody. (b) TE1 cells were co-transfected with
the IKKa reporter plasmid (0.1mg), pRL-null plasmid (0.02mg), and expression
vectors for DNp63a wt and mutants L518V, Q536L, FS, C306R, 1743 DelAA,
and E639X (1.5 mg). After 24 hours, cells were harvested and luciferase activity
was determined. (c) TE1 cells were transfected with the indicated plasmids
and subjected to total mRNA extraction. IKKa mRNA expression was
determined by RT-qPCR after normalization to ARP expression.
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However, experiments performed in primary human kerati-
nocytes, in which DNp63 was selectively downregulated,
clearly indicate that DNp63a is required for the induction of
IKKa during keratinocyte differentiation, confirming the
essential role of DNp63 in the regulation of proliferation
and differentiation of mature keratinocytes (Truong et al.,
2006; Koster et al., 2007). The role of IKKa as a critical
regulator of keratinocyte proliferation was further demon-
strated by its ability to rescue normal cell cycle exit in
DNp63-downregulated cells. The same pathway was inde-
pendently identified by Candi et al. (2006); however, their
data suggest that both classes of p63 isoforms, TA and DN,
could induce IKKa expression when overexpressed in SAOS2
cells. This apparent discrepancy with our data can be
explained by the use of different cell types.
The EEC, SHFM, AEC, and LMS syndromes are caused by
mutations in the p63 gene. These syndromes show clinical
variability, with sparse hair, dry skin, pilosebaceous gland
dysplasia, and oligodontia as well as variable abnormalities
of hands and feet, ranging from severe ectrodactyly in EEC
patients to mild defects in AEC patients (Brunner et al., 2002;
Rinne et al., 2006). We hypothesized that alterations in IKKa
expression levels, caused by the inability of mutant p63
proteins to activate IKKa transcription at critical steps during
epidermal development, may contribute to the development
of some of the clinical phenotypes observed in ectodermal
dysplasia patients. Indeed, our data demonstrate that most of
the mutant p63 proteins used in this study displayed an
altered ability to induce transcription from an IKKa reporter
and to induce expression of IKKa mRNA. These defects are
particularly evident in DNp63 proteins carrying mutations
found in patients with AEC, which display skin abnormalities,
and less in DNp63 proteins carrying mutations found in
ectodermal dysplasias lacking a skin phenotype (SHFM).
Moreover, a subset of mutant DNp63 proteins expressed in
EEC (DNp63FS), AEC (DNp63-536), or LMS (DNp63DAA)
patients exhibit a dominant-negative activity toward the
induction of IKKa transcripts by wt DNp63a. This effect
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Figure 5. Dominant-negative activity of p63 mutants on DNp63-induced IKKa expression. (a) TE1 cells were transfected with wild-type DNp63a alone or in
combination with the indicated expression plasmids. After 24 hours, cells were harvested and the IKKa mRNA expression normalized to ARP levels was
determined by RT-qPCR. (b) TE1 cells were transfected with wild-type DNp63a alone or in combination with the indicated expression plasmids. Cells were
harvested after 36 hours, and total cell lysate was immunoblotted with specific antibodies (Abs). The relative amount of endogenous IKKa protein was quantified
by densitometric analysis. (c) Skin sections from healthy donors (upper panels) and from the lesional skin of a patient affected by AEC syndrome (I537T
mutation in the SAM domain of p63) (lower panels) were subjected to immunohistochemistry with specific Abs to reveal the pattern of expression of IKKa
(left panels), K1 (middle panels), and the proliferation marker Ki-67 (right panels). Scale bar¼ 20mm. Total RNA extracted from normal skin sections and
from AEC skin sections was subjected to RT-qPCR to determine IKKa mRNA expression levels (right histogram). Bars represent the mean expression (±SD)
obtained from three different sections of normal subjects and of the AEC patient.
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correlates with the observation of the heterozygous nature of
p63-dependent ectodermal dysplasias supporting the hypoth-
esis that some clinical defects observed in ectodermal
dysplasia patients may be due to the ability of mutant p63
proteins to prevent gene activation by wt p63. Recent
observations confirm that the selective and conditional
downregulation of DNp63 in the epidermis of newborn mice
results in IKKa mRNA downregulation and in a clinical
phenotype similar to that observed in AEC syndrome (Koster
et al., 2007). Furthermore, IKKa downregulation was also
observed in the lesional skin of AEC patients at both protein
and mRNA levels (Figure 5c), further reinforcing the idea that
IKKa activation by p63 may play a role in the pathogenesis of
skin defects in ectodermal dysplasias. Although additional
in vivo models (for example, AEC knockin mice) are
necessary to confirm our conclusions, the data reported in
this study suggest that IKKa may act as a critical p63
downstream target gene in the regulation of epidermal
morphogenesis and in the development of a subset of
ectodermal dysplasias.
MATERIALS AND METHODS
Cell lines
U2OS (wt-p53 osteosarcoma cells) were grown in DMEM containing
10% regular fetal bovine serum and antibiotics (100Uml1 penicillin
and 10mgml1 streptomycin) at 37 1C. TE1 cells (esophageal SCC
cell line) were cultured in RPMI medium containing 10% regular fetal
bovine serum and antibiotics (100Uml1 penicillin and 10mgml1
streptomycin) at 37 1C. Primary mouse keratinocytes were isolated
from newborn mice and cultured at 37 1C in low calcium (0.05mM
CaCl2) keratinocyte basal medium (Clonetics, San Diego, CA) and
EGF (10ngml1). Cryopreserved NHEKs were obtained from
Clonetics and grown on calf skin collagen (Sigma, Milan, Italy)
coated dishes in serum-free keratinocyte basal medium. Third-
passage NHEK cells were used for transfection experiments.
Reporter plasmids, transient transfections, viral infection, and
luciferase assays
Expression plasmids encoding for TAp63a, TAp63b, TAp63g,
DNp63a, DNp63b, DNp63g, and DNp63a mutants L518V and
Q536L (AEC), FS (1689insA) and C306R (EEC), 1743 DelAA (LMS),
and E639X (SHFM) were obtained from L. Guerrini (University of
Milan, Italy). The p53-encoding plasmid was a kind gift of M. Oren
(The Weizmann Institute). IKKa-expressing adenovirus was already
described (Hu et al., 1999). Viral infections were conducted by
incubating primary keratinocytes in serum- and Ca2þ -free Eagle’s
minimum essential medium with the appropriate adenovirus at a
multiplicity of infection of 50 for 3 to 4 hours, followed by culture in
normal growth medium. Under these conditions, X90% of primary
mouse keratinocytes were infected, as confirmed by X-gal staining in
cells infected with Ad-LacZ.
To generate the IKKa-luc reporter plasmid, normal human
genomic DNA was amplified with primers (hIKKaprom sense 50-CA
GTGCTCAACATTCTGGTTGC-30 and hIKKaprom antisense 50-GCC
TCAGGTTCCACAGTTGT-30) spanning the 1,182 to þ 45 region
relative to the IKKa transcription initiation site. The PCR product was
cloned into the SmaI site of the pGL3 basic plasmid (Promega Inc.,
Madison, WI) and verified by sequencing. The analysis of putative
p53 responsive elements was performed using PatSearch software
(http://bighost.area.ba.cnr.it/BIG/PatSearch/) and the following
strings:
p1¼ rrrcwwgyyy[3,0,0] 0.13 p2¼ rrrcwwgyyy[3,0,0];
p1/p2:(p3¼ rrrcwwgyyyrrrcwwgyyy[3,0,0]
Transfection and luciferase activity assay
For reporter gene assays, cells were transiently co-transfected with
the IKKa-luc reporter and mammalian expression plasmids encoding
for TAp63a, TAp63b, TAp63g, DNp63a, DNp63b, DNp63g, p53,
and DNp63a mutants L518V, Q536L, FS, C306R, 1743 DelAA, and
E639X. Cells were seeded in 12-well plates and transfected with
0.1 mg IKKa-luc, 0.02 mg of pRL-null plasmid, and 1.5 mg of the
indicated expression plasmids using Lipofectamine 2000 (Invitrogen
Inc., Carlsbad, CA). At 24 hours post-transfection, cell extracts were
prepared with 1 lysis buffer, and the luciferase activity was
measured using the Dual-Luciferase Kit (Promega Inc.) on a Triathler
luminometer (Hidex). Results from experiments, performed three
times in triplicate wells, are expressed as relative luciferase activity
after normalization with the pRL-null plasmid as internal control.
Basal activity of the reporter was set to 1. Each histogram bar
represents the mean of three independent transfection experiments
performed in triplicate. Standard deviations are indicated.
RNA interference
siRNA duplexes targeting DNp63, TAp63, and GFP were obtained
from MWG-Biotech (Ebersberg, Germany). Sequences are available
in the Supplementary Online Material
Primary keratinocytes plated on collagen-coated 35mm dishes
were transfected with 0.5 mg of siRNA per dish using Lipofectamine
2000 (Invitrogen).
Antibodies, immunoblotting, and cell fractionation
The Abs used were polyclonal anti-actin (C-11), monoclonal
b-tubulin (3F3-G2), monoclonal g-tubulin (14C11), monoclonal
anti-p63 (4A4), polyclonal anti-p63 (H-137), monoclonal anti-p53
(DO-1), and monoclonal anti-HA (F-7), and they were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); monoclonal
anti-IKKa and anti-Ki67 Ab was from BD Pharmingen (San Diego,
CA); anti-K1 was purchased from Covance (Princeton, NJ).
For immunoblotting assays, cells were lysed in 50mM Tris, pH 8,
120mM NaCl, and 0.5%. NP-40, and protein concentration was
determined by the Bio-Rad dye-binding assay (Irvine, CA). Total cell
extract of 50 mg was loaded on denaturing SDS-PAGE gels and
blotted onto a polyvinylidene difluoride membrane. Western blot
analysis was performed using the enhanced chemiluminescence
system (Amersham Pharmacia Biotech Inc., Uppsala, Sweden).
For cyto/nuclear extraction, cells were washed twice in ice-cold
PBS. Cells were then pelleted by centrifugation at 1,400 r.p.m. for
5minutes, washed once in (1ml) buffer A (10mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.9), 10mM
KCl, 0,1mM EDTA, 0,1mM EGTA (ethylene glycol bis(b-aminoethyl-
ether)-N,N,N0,N0,-tetraacetic acid), 1mM PMSF (phenylmethyl-
sulfonyl fluoride), and 1mM dithiothreitol), and centrifuged at
10,000 r.p.m. for 10minutes. Cell pellets were resuspended in buffer
A containing 0.1% (v/v) NP-40 for 10minutes on ice and lysed.
Subsequently, cells were centrifuged at 10,000 r.p.m. for 10minutes.
The supernatant was harvested and the nuclear pellet was extracted
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with buffer C (20mM Hepes (pH 7.9), 400mM NaCl, 1mM EGTA,
1mM EDTA, 20% (w/v) glycerol, and 1mM PMSF) for 15minutes on
ice. After incubation, the nuclei were centrifuged at 10,000 r.p.m. for
10minutes and the supernatant was diluted with four volumes of
buffer D (10mM Hepes (pH 7.9), 50mM KCl, 0.2mM EDTA, 25%
(w/v) glycerol, 0.5mM PMSF, and 1mM DTT).
mRNA expression analysis
For quantitative real-time PCR, total RNA was extracted from cells
using the Trizol Reagent (Invitrogen). One microgram of total RNA
was reverse transcribed with GeneAmp RNA PCR (Applied
Biosystems Italy, Milan, Italy). For RT-qPCR in mouse keratinocytes,
the TaqMan Universal PCR Master Mix (Applied Biosystems Italy)
was used for PCR amplification of the cDNA using the Applied
Biosystem 7300 real-time PCR system. Each mRNA was normalized
to the levels of cyclophilin mRNA for each reaction, and the relative
quantification of each gene was determined using the comparative
CT method. Primer sequences for IKKa and K10 are available in
Supplementary Online Material.
For RT-qPCR in human cells, the reverse transcriptase reaction
products were used for quantitative real-time PCR amplification,
which was performed with the MyiQ Single-Color Real-Time
Detection System for quantification with SYBR Green and melting
curve analysis (Bio-Rad, Richmond, CA). The hARP gene (human
acidic ribosomal protein P0) was used for normalization. Total RNA
was extracted from formalin-fixed, paraffin-embedded sections by the
Optimum FFPE RNA Isolation Kit (Ambion, Austin, TX) according to
the manufacturer’s protocol. Primer sequences for IKKa, K1, p63, and
ARP are available in Supplementary Online Material.
ChIP assay
For ChIP assays, primary human keratinocytes (NHEK) and U2OS
cells were used. ChIP assays were performed as described previously
(Costanzo et al., 2002). Briefly, after fixing in 1% formaldehyde,
cells were lysed for 5minutes in 50mM Tris, pH 8.0, 2mM EDTA,
0.1% NP-40, and 10% glycerol supplemented with protease
inhibitors. Nuclei were re-suspended in 50mM Tris, pH 8.0, 1%
SDS, and 5mM EDTA. Chromatin was sheared by sonication,
centrifuged, and diluted 10-fold in 50mM Tris, pH 8.0, 0.5% NP-
40, 0.2 M NaCl, and 0.5mM EDTA. After pre-clearing with a 50%
suspension of salmon sperm-saturated protein A, lysates were
incubated at 4 1C overnight with anti-p63, anti-HA, or anti-Myc
Abs. Immune complexes were collected with sperm-saturated
protein A, washed three times with high salt buffer (20mM Tris, pH
8.0, 0.1% SDS, 1% NP-40, 2mM EDTA, and 500mM NaCl), and
three times with 1 Tris/EDTA (TE). Immune complexes were
extracted in 1 TE containing 1% SDS, and protein–DNA cross-
links were reverted by heating at 65 1C overnight. DNA was
extracted by phenol–chloroform, and 1/20th of the immunoprecipi-
tated DNA was used in each PCR reaction.
PCR reactions were performed for 25–35 cycles of denaturation at
95 1C for 45 seconds, annealing at 55–57 1C for 45 seconds, and
extension at 72 1C for 45 seconds.
Primer sequences are reported in online Supplementary Material.
Immunohistochemistry and immunofluorescence
Punch biopsy specimens (4mm) were taken from normal skin of
healthy volunteers (n¼ 4). The Declaration of Helsinki protocols
were followed and patients gave written approved consent before
biopsy. A patient affected by AEC (I537T mutation in p63) was
subjected to skin biopsy on the lesional skin after obtaining informed
consent from his parents. Paraffin-embedded 5mm skin sections
were kept at 60 1C for 1 hour and then incubated at 80 1C overnight
in citrate buffer pH 6 (DAKO Italia, Milan, Italy). The sections were
incubated for 1 hour at room temperature with the appropriate
dilution of anti-human IKKa monoclonal Ab, anti-K1, anti-Ki67, or
control mouse Igs. Sections were stained with an avidin–biotin–per-
oxidase technique (DAKO Italia) by using 3,30-diaminobenzidine as
a substrate (DAKO Italia). For BrdU incorporation assay, we made
use of BrdU Immunohistochemistry Assay Kit (Invitrogen) according
to the manufacturer’s protocol. For indirect immunofluorescence
labeling, double labeling was performed on skin biopsies after
deparaffination and rehydration. The primary Abs used were
monoclonal anti-p63 (4A4) (1:100) and rabbit polyclonal anti-IKKa
(1:50). Secondary Abs were Alexa 488-conjugated goat anti-rabbit
(Molecular Probes, Milan, Italy) and Texas Red-conjugated goat anti-
mouse (Molecular Probes). To determine nonspecific binding,
staining control experiments with secondary Ab without primary
Ab were also performed. Samples were examined with the use of a
Zeiss LSM 410 laser-scanning confocal microscope. The picture
shown in Figure 2b is representative of four different biopsies taken
from four healthy donors.
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SUPPLEMENTARY MATERIAL
Figure S1. Total cell lysate (20 mg) from experiment described in Figure 1B
right panel was immunoblotted with specific antibodies to detect expression
levels of p63 isoforms, p73 isoforms and p53.
Figure S2. Primary mouse keratinocytes were transfected with indicated
siRNA and then kept under proliferating or differentiating (2mM CaCl2)
conditions.
Figure S3. Dominant-negative activity of p63 mutants on differentiation-
induced IKKa transcription.
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